Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA
Authors' conclusion
Body weight was associated with the initial response to SC tocilizumab, although the difference in response was small, but not drug persistence.
Study context
- Population
- Patients with rheumatoid arthritis (RA) administered tocilizumab in the BSRBR-RA
- Participants
- 2,612 patients
- Exposure
- Every 10 kg increase in body weight, by route of tocilizumab administration (intravenous (IV) vs subcutaneous (SC))
- Outcome
- 6-month change in DAS28 per 10 kg increase in body weight (adjusted regression coefficient)
- Follow-up
- 6 months
Methodological detailsregistry (BSRBR-RA), stratified by route of administration, adjusted regression models, multiple imputation
- Registry (BSRBR-RA)
- Stratified by route of administration
- Adjusted regression models
- Multiple imputation
Main finding
As reported in the abstract
Adjusted regression coefficient
0.01
95% CI −0.04 to 0.07
All
Adjusted regression coefficient
−0.03
95% CI −0.1 to 0.5
IV
Adjusted regression coefficient
0.1
95% CI 0.02–0.2
SC
Observational data: associations, not effects.
Further findings
DAS28 remission and EULAR response
- Body weight not associated with odds of achieving DAS28 remission or EULAR response
Persistence of IV or SC tocilizumab
- No significant association between body weight and persistence of IV or SC tocilizumab
Original publication
Association between body weight and tocilizumab effectiveness in rheumatoid arthritis: results from the BSRBR-RA. Rheumatology (Oxford). Published 14 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →